ASCO issues guidelines for early CRC

  • Costas-Chavarri A & al.
  • J Glob Oncol
  • 1 Feb 2019

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The American Society of Clinical Oncology (ASCO) has released recommendations for the treatment of early-stage colorectal cancer (CRC) based on a systematic review of 12 existing guidelines.

Why this matters

  • New guidelines provide recommendations for different resource settings.

Key points

  • Stage I-III colon cancer optimal treatment:
    • Most patients are treated with surgery, either laparoscopic or open resection along with draining nodal stages.
    • Postsurgical chemotherapy, when available, is an option for patients with stage III tumors and high-risk stage II tumors.
    • Adjuvant chemotherapy should be used in cases of high-risk obstructing colon cancer.
  • Stage I-III rectal cancer treatment:
    • The primary mode of treatment is surgery, with the specific procedure depending on the resource-level setting.
    • Chemotherapy and/or radiotherapy is recommended, based on availability and potential risk factors, for patients with clinically resectable cT3N0 rectal cancer, high-risk stage II rectal cancer, and all patients with stage III rectal cancer. Preoperative risk factors should determine use of neoadjuvant therapy.
  • Posttreatment surveillance for CRC:  
    • Follow-up should include medical history, physical examinations, carcinoembryonic antigen testing, imaging, and surveillance endoscopy. The follow-up frequency and other details depend on cancer stage and resource setting.
  • Additional data, including evidence tables, is available online.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit